triple capsid mutant based NAGLU gene therapy (Lacerta Therapeutics/University of Florida)

N/A

Report date: 2025/01/26 17:48:02

Base Information

Drug Nametriple capsid mutant based NAGLU gene therapy (Lacerta Therapeutics/University of Florida)
Drug Alias NameAAV8 based NAGLU gene therapy (Lacerta Therapeutics)AAVtcm8-coNAGLUNAGLU gene therapy (Lacerta Therapeutics, University of Florida)
ClassificationOther
Mechanisms of ActionAlpha-N-acetylglucosaminidase stimulants
TargetsAlpha-N-acetylglucosaminidase
Therapy Area/IndicationsMucopolysaccharidosis III
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesUniversity Of Florida
China Registration ClassN/A

Develop Information

Active CompaniesLacerta Therapeutics IncUniversity Of Florida
Inactive CompaniesN/A
Active IndicationsMucopolysaccharidosis III
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A